FDA Approved: INCRELEX — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Increlex (mecasermin) from Ipsen Biopharmaceuticals, Inc., resulting in updated labeling for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Failure in Children Due to Severe Insulin-like Growth Factor-1 Deficiency
• Laron Syndrome

Drugs mentioned

• INCRELEX (Mecasermin)

Snippet

SUPPL AP for INCRELEX (MECASERMIN)